ISMP
ISMP ISMP
 
     
 
ISMP
A shortage of everything except errors: Harm associated with drug shortages
April 19, 2012

In our November 3, 2011 newsletter, we asked hospital pharmacy staff to let us know if the drug shortage problem in the US has continued to result in harmful outcomes for hospitalized patients. At that time, an Associated Press article had just reported 15 deaths in the prior 15 months that were linked directly to drug shortages.1 (Thirteen of these deaths had also been reported to ISMP.) In response to our request for information, nearly a hundred practitioners took our short survey and strengthened our belief that the ongoing drug shortage crisis is extracting a significant toll on patient safety. 

Survey respondents provided a bleak picture of certain and suspected patient harm that has resulted during the past year (March 2011 to March 2012) due to crucial drug shortages. The medications most commonly involved in the reported adverse events include: chemotherapy (27%), particularly DOXOrubicin; opioid analgesics (17%), mostly fentaNYL and morphine; electrolytes (7%); antibiotics (5%); phentolamine (4%); and phytonadione (4%). See Table 1 (PDF version of the newsletter) for a list of medications involved in more than one reported adverse outcome.













The types of harm reported by respondents included prolonged duration or progression of a disease, transient and permanent injuries, and death (n=4). Table 2 (on page 2 in the PDF version of the newsletter) provides examples of the types of harm reported; in many cases, patients suffered more than one type of harm from the drug shortage. Problems associated with a drug shortage that resulted in harm fell primarily into four categories:
 

  1. Alternative medication provided, but it was not the drug of choice, which led to inadequate treatment (35%)
  2. An error with an alternative drug or form/strength of a drug used as a substitution for the drug in short supply (27%)
  3. An omission of vital medication leading to non-treatment of the patient (27%)
  4. An error when a hospital pharmacy attempted to compound a product or drug strength no longer available (6%).





 Events involving adults and older adults

The majority of harmful events reported by respondents affected adults between the ages of 19 and 64 years (57%) and 65 to 80 years (20%). A number of examples follow. 

  • Unfamiliarity with BREVITAL SODIUM (methohexital), used as a substitute for propofol, resulted in a serious dilution error during reconstitution of the powder. The patient ultimately received a massive overdose of the drug and died despite resuscitation efforts.
  • Prior to a midazolam shortage, the anesthesia department had been supplied with 5 mg/5 mL vials of midazolam. Once the medication was withdrawn into a syringe, some anesthesiologists had developed an unsafe habit of determining whether the syringe was new or used by the remaining volume in the syringe; anything less than 5 mL signaled a “used” syringe. During the shortage, 2 mg/2 mL vials of midazolam were sometimes dispensed in place of the 5 mg/5 mL vials (same concentration). With the 2 mL vials, syringe volumes of less than 5 mL could no longer signal a “used” syringe since a new syringe could contain just 2 mL. Fluctuating volumes of midazolam vials contributed to using the same syringe to administer midazolam to two patients. A 5 mg/5 mL vial of midazolam had been withdrawn into a syringe and used to administer 3 mg (3 mL) of the medication. The remaining 2 mg (2 mL) in the syringe was mistakenly thought to be a new syringe of midazolam from a 2 mg/mL vial, which was administered to another patient. 
  • During a fentaNYL shortage, a patient who was unable to take morphine or HYDROmorphone was prescribed meperidine. She experienced extreme nausea and vomiting unrelieved by ondansetron.
  • During a morphine shortage, a physician prescribed, a pharmacist approved, and a nurse administered HYDROmorphone 2 mg IV to an opioid-naïve patient (approximately equivalent to 14 mg of morphine). The patient required naloxone and monitoring in a critical care unit.
  • During a shortage of calcium gluconate, calcium chloride was administered IV to treat an electrolyte imbalance. The higher osmolarity of the undiluted calcium chloride solution caused permanent vascular and integumentary harm after it infiltrated into the surrounding tissue.
  • A cancer patient had progression of her disease, possibly hastening her death, because she could not complete treatment with DOXOrubicin due to a shortage. It was too late to switch to another protocol.
  • During a shortage of multivitamins, a patient receiving parenteral nutrition without multivitamins was given an oral multivitamin supplement. The patient developed signs of Wernicke encephalopathy (confusion, slurred speech, loss of coordination, unsteady gait, blurred vision, fatigue and sleepiness), at which time it was discovered that the oral multivitamin did not contain thiamine.              
  • Premixed solutions of bupivacaine 0.5% with EPINEPHrine 1:200,000 were not available. Pharmacy mixed a small batch of solutions for anesthesia but added too much EPINEPHrine during admixture. Two patients developed hypertension, ventricular fibrillation, and pulmonary edema, requiring extended hospitalization in a critical care unit. One patient required mechanical ventilation.  

 Events involving infants and children

 Twenty percent of the events reported in the survey involved pediatric patients between the ages of 0 to 1 year (12%) and 2 to 10 years (8%). Examples within these age groups are provided below.

  • During a cysteine shortage, inability to add this product to amino acids led to iatrogenic fractures in two infants, an injury not seen previously in the facility despite years of treating infants on long-term parenteral nutrition. (Cysteine enhances the solubility of calcium and phosphates.)
  • Using TRAVASOL (amino acid injection) during a shortage of TROPHAMINE (amino acid injection preferred for children) in a low-birth-weight neonate’s parenteral nutrition solution led to precipitation of calcium and phosphate, which blocked the child’s Broviac catheter, requiring surgical replacement.
  • Ammonium chloride was used during a shortage of arginine to treat hypochloremic alkalosis. Pharmacy staff failed to dilute the ammonium chloride prior to dispensing it (arginine doesn’t require dilution). The infant experienced seizures during the infusion but recovered. 
  • Stem cell transplant was delayed for a second time in a young child with acute lymphocytic leukemia (ALL) because there was no busulfan to be found in the state or through the wholesaler. Eventually, a nurse drove 3 hours to another state after completing a full evening shift to borrow the needed doses. Staff are unable to determine if the delays affected the success of the treatment. 
  • During a shortage of DAUNOrubicin, children received induction treatment for ALL or AML (acute myeloid leukemia) with DOXOrubicin (typically not used in children) and experienced severe mucositis and gastrointestinal bleeding.

We sincerely thank our survey respondents for allowing us a glimpse of the enormous toll that drug shortages are taking on patients and their healthcare providers who are faced with the problem on a daily basis. With only about a hundred practitioners responding to our survey, the adverse events related to drug shortages reported to ISMP likely represent just a fraction of the actual harm from drug shortages occurring today. Just this week, the results of another survey conducted by the American Society of Anesthesiologists (ASA) revealed that seven anesthesiologists had reported shortages that led to death in their patients (http://abcnews.go.com/Health/abc-news-exclusive-anesthesia-drug-shortages/story?id=16123792). The seven anesthesiologists responded to the question "How has a drug shortage impacted your patients?" by checking the option, "Has resulted in death of patient," according to ABCNews.com. One of the four deaths reported to ISMP involved a general anesthetic agent used as an alternative medication during a propofol shortage. A similar ASA survey in 2011 included reports of two patient deaths.      

ISMP will continue its efforts, in cooperation with the American Society of Health-System Pharmacists (ASHP), the US Food and Drug Administration, and many other partner organizations (e.g., American Hospital Association, American Society of Clinical Oncology, American Society of Anesthesiologists) to articulate the scope of this problem, and to develop a plan to reduce the occurrence of drug shortages and better manage them when they occur. We will keep readers well informed of progress to this end. Meanwhile, we offer some stop-gap guidance for managing drug shortages on a local level within healthcare organizations at: www.ismp.org/Newsletters/acutecare/articles/20101007.asp.

Reference 1: Johnson LA. Drug shortage stirs fear. Associated Press. Philly.com. September 24, 2011. www.ismp.org/sc?k=dssf
Resources
Acute Care Main Page
Current Issue
Past Issues
Highlighted articles
Action Agendas - Free CEs
Special Error Alerts
Subscribe
Newsletter Editions
Acute Care
Community/Ambulatory
Nursing
Long Term Care
Consumer
Home | Contact UsEmployment  |   Legal Notices | Privacy Policy | Help Support ISMP
 Med-ERRS | Medication Safety Officer Society Medication Safety Officers Society | Consumer Medication Safety For consumers
ISMP Canada | ISMP Spain  | ISMP Brasil  | International Group  | Pennsylvania Patient Safety Authority

200 Lakeside Drive, Suite 200, Horsham, PA 19044, Phone: (215) 947-7797,  Fax: (215) 914-1492
© 2014 Institute for Safe Medication Practices. All rights reserved

ISMP
ISMP